Panitumumab (INN), formerly ABX-EGF, is a fully human monoclonal antibody specific to the epidermal growth factor receptor (also known as EGF receptor, EGFR, ErbB-1 and HER1 in humans).
Market Analysis and Insights: Global Panitumumab Market
The global Panitumumab market is projected to grow from US$ million in 2023 to US$ million by 2029, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Panitumumab is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The China market for Panitumumab is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The Europe market for Panitumumab is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global key companies of Panitumumab include Amgen. etc. in 2022, the global top five players had a share approximately % in terms of revenue.
Report Includes
This report presents an overview of global market for Panitumumab market size. Analyses of the global market trends, with historic market revenue data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.
This report researches the key producers of Panitumumab, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Panitumumab, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Panitumumab revenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global Panitumumab market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2029. Evaluation and forecast the market size for Panitumumab revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Amgen. etc.
By Company
Amgen
Segment by Type
100 mg/5 mL single-dose vials
400 mg/20 mLsingle-dose vials
Segment by Application
Hospital
Drug store
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East, Africa, and Latin America
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Panitumumab in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Panitumumab companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: China by type and by application revenue for each segment.
Chapter 9: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Panitumumab revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Panitumumab Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 100 mg/5 mL single-dose vials
1.2.3 400 mg/20 mLsingle-dose vials
1.3 Market by Application
1.3.1 Global Panitumumab Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Drug store
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Panitumumab Market Perspective (2018-2029)
2.2 Global Panitumumab Growth Trends by Region
2.2.1 Panitumumab Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Panitumumab Historic Market Size by Region (2018-2023)
2.2.3 Panitumumab Forecasted Market Size by Region (2024-2029)
2.3 Panitumumab Market Dynamics
2.3.1 Panitumumab Industry Trends
2.3.2 Panitumumab Market Drivers
2.3.3 Panitumumab Market Challenges
2.3.4 Panitumumab Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Panitumumab by Players
3.1.1 Global Panitumumab Revenue by Players (2018-2023)
3.1.2 Global Panitumumab Revenue Market Share by Players (2018-2023)
3.2 Global Panitumumab Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Panitumumab, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Panitumumab Market Concentration Ratio
3.4.1 Global Panitumumab Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Panitumumab Revenue in 2022
3.5 Global Key Players of Panitumumab Head office and Area Served
3.6 Global Key Players of Panitumumab, Product and Application
3.7 Global Key Players of Panitumumab, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Panitumumab Breakdown Data by Type
4.1 Global Panitumumab Historic Market Size by Type (2018-2023)
4.2 Global Panitumumab Forecasted Market Size by Type (2024-2029)
5 Panitumumab Breakdown Data by Application
5.1 Global Panitumumab Historic Market Size by Application (2018-2023)
5.2 Global Panitumumab Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Panitumumab Market Size (2018-2029)
6.2 North America Panitumumab Market Size by Type
6.2.1 North America Panitumumab Market Size by Type (2018-2023)
6.2.2 North America Panitumumab Market Size by Type (2024-2029)
6.2.3 North America Panitumumab Market Share by Type (2018-2029)
6.3 North America Panitumumab Market Size by Application
6.3.1 North America Panitumumab Market Size by Application (2018-2023)
6.3.2 North America Panitumumab Market Size by Application (2024-2029)
6.3.3 North America Panitumumab Market Share by Application (2018-2029)
6.4 North America Panitumumab Market Size by Country
6.4.1 North America Panitumumab Market Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Panitumumab Market Size by Country (2018-2023)
6.4.3 North America Panitumumab Market Size by Country (2024-2029)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Panitumumab Market Size (2018-2029)
7.2 Europe Panitumumab Market Size by Type
7.2.1 Europe Panitumumab Market Size by Type (2018-2023)
7.2.2 Europe Panitumumab Market Size by Type (2024-2029)
7.2.3 Europe Panitumumab Market Share by Type (2018-2029)
7.3 Europe Panitumumab Market Size by Application
7.3.1 Europe Panitumumab Market Size by Application (2018-2023)
7.3.2 Europe Panitumumab Market Size by Application (2024-2029)
7.3.3 Europe Panitumumab Market Share by Application (2018-2029)
7.4 Europe Panitumumab Market Size by Country
7.4.1 Europe Panitumumab Market Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Panitumumab Market Size by Country (2018-2023)
7.4.3 Europe Panitumumab Market Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Panitumumab Market Size (2018-2029)
8.2 China Panitumumab Market Size by Type
8.2.1 China Panitumumab Market Size by Type (2018-2023)
8.2.2 China Panitumumab Market Size by Type (2024-2029)
8.2.3 China Panitumumab Market Share by Type (2018-2029)
8.3 China Panitumumab Market Size by Application
8.3.1 China Panitumumab Market Size by Application (2018-2023)
8.3.2 China Panitumumab Market Size by Application (2024-2029)
8.3.3 China Panitumumab Market Share by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Panitumumab Market Size (2018-2029)
9.2 Asia Panitumumab Market Size by Type
9.2.1 Asia Panitumumab Market Size by Type (2018-2023)
9.2.2 Asia Panitumumab Market Size by Type (2024-2029)
9.2.3 Asia Panitumumab Market Share by Type (2018-2029)
9.3 Asia Panitumumab Market Size by Application
9.3.1 Asia Panitumumab Market Size by Application (2018-2023)
9.3.2 Asia Panitumumab Market Size by Application (2024-2029)
9.3.3 Asia Panitumumab Market Share by Application (2018-2029)
9.4 Asia Panitumumab Market Size by Region
9.4.1 Asia Panitumumab Market Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Panitumumab Market Size by Region (2018-2023)
9.4.3 Asia Panitumumab Market Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Panitumumab Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America Panitumumab Market Size by Type
10.2.1 Middle East, Africa, and Latin America Panitumumab Market Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Panitumumab Market Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Panitumumab Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Panitumumab Market Size by Application
10.3.1 Middle East, Africa, and Latin America Panitumumab Market Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Panitumumab Market Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Panitumumab Market Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Panitumumab Market Size by Country
10.4.1 Middle East, Africa, and Latin America Panitumumab Market Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Panitumumab Market Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Panitumumab Market Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Amgen
11.1.1 Amgen Company Details
11.1.2 Amgen Business Overview
11.1.3 Amgen Panitumumab Introduction
11.1.4 Amgen Revenue in Panitumumab Business (2018-2023)
11.1.5 Amgen Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Amgen
*If Applicable.